Cost-effectiveness of polatuzumab vedotin plus chemoimmunotherapy for untreated diffuse large B-cell lymphoma in China
Abstract In recent years, antibody-drug conjugates have become clinically significant in oncology therapeutics. Results from the POLARIX trial revealed that polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) versus rituximab plus cyclophosph...
Furkejuvvon:
| Váldodahkkit: | , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Nature Portfolio
2025-08-01
|
| Ráidu: | Scientific Reports |
| Fáttát: | |
| Liŋkkat: | https://doi.org/10.1038/s41598-025-15477-9 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|